Maxigen Biotech Inc (1783) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Maxigen Biotech Inc (1783) has a cash flow conversion efficiency ratio of 0.055x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$81.78 Million ≈ $2.58 Million USD) by net assets (NT$1.47 Billion ≈ $46.43 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Maxigen Biotech Inc - Cash Flow Conversion Efficiency Trend (2009–2024)
This chart illustrates how Maxigen Biotech Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Maxigen Biotech Inc carry for a breakdown of total debt and financial obligations.
Maxigen Biotech Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Maxigen Biotech Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eolus Vind AB (publ)
ST:EOLU-B
|
0.793x |
|
Amorepacific Group
KO:002795
|
-0.003x |
|
Lassila &Tikanoja Oyj
HE:LAT1V
|
0.070x |
|
Southern Acids (M) Bhd
KLSE:5134
|
0.052x |
|
Bajaj Healthcare Limited
NSE:BAJAJHCARE
|
0.030x |
|
BIOCELTIX S.A. ZY -10
F:XI3
|
N/A |
|
Panasonic Manufacture Malaysia
KLSE:3719
|
0.002x |
|
Sat Industries Limited
NSE:SATINDLTD
|
0.006x |
Annual Cash Flow Conversion Efficiency for Maxigen Biotech Inc (2009–2024)
The table below shows the annual cash flow conversion efficiency of Maxigen Biotech Inc from 2009 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Maxigen Biotech Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$1.38 Billion ≈ $43.32 Million |
NT$298.22 Million ≈ $9.40 Million |
0.217x | +72.42% |
| 2023-12-31 | NT$1.36 Billion ≈ $42.88 Million |
NT$171.20 Million ≈ $5.39 Million |
0.126x | -39.27% |
| 2022-12-31 | NT$1.30 Billion ≈ $40.82 Million |
NT$268.34 Million ≈ $8.45 Million |
0.207x | +101.08% |
| 2021-12-31 | NT$1.14 Billion ≈ $35.97 Million |
NT$117.59 Million ≈ $3.70 Million |
0.103x | +19.10% |
| 2020-12-31 | NT$860.23 Million ≈ $27.10 Million |
NT$74.39 Million ≈ $2.34 Million |
0.086x | -22.02% |
| 2019-12-31 | NT$851.32 Million ≈ $26.82 Million |
NT$94.42 Million ≈ $2.97 Million |
0.111x | -45.19% |
| 2018-12-31 | NT$842.98 Million ≈ $26.56 Million |
NT$170.58 Million ≈ $5.37 Million |
0.202x | +291.31% |
| 2017-12-31 | NT$796.25 Million ≈ $25.09 Million |
NT$41.18 Million ≈ $1.30 Million |
0.052x | +16.39% |
| 2016-12-31 | NT$781.38 Million ≈ $24.62 Million |
NT$34.72 Million ≈ $1.09 Million |
0.044x | +133.57% |
| 2015-12-31 | NT$829.86 Million ≈ $26.14 Million |
NT$-109.85 Million ≈ $-3.46 Million |
-0.132x | -703.35% |
| 2014-12-31 | NT$877.01 Million ≈ $27.63 Million |
NT$-14.45 Million ≈ $-455.29K |
-0.016x | +34.46% |
| 2013-12-31 | NT$888.39 Million ≈ $27.99 Million |
NT$-22.34 Million ≈ $-703.71K |
-0.025x | -155.33% |
| 2012-12-31 | NT$385.66 Million ≈ $12.15 Million |
NT$17.53 Million ≈ $552.17K |
0.045x | +121.89% |
| 2011-12-31 | NT$369.25 Million ≈ $11.63 Million |
NT$-76.64 Million ≈ $-2.41 Million |
-0.208x | -389.53% |
| 2010-12-31 | NT$395.39 Million ≈ $12.46 Million |
NT$-16.76 Million ≈ $-528.16K |
-0.042x | -168.87% |
| 2009-12-31 | NT$313.03 Million ≈ $9.86 Million |
NT$19.27 Million ≈ $607.14K |
0.062x | -- |
About Maxigen Biotech Inc
Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices and cosmetic products in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone materials; beauty care products; and medical devices for ophthalmology, otola… Read more